Journal article
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease
Abstract
Importance: Patients with symptomatic lower extremity peripheral artery disease (LE-PAD) experience an increased risk of major vascular events. There is limited information on what clinical features of symptomatic LE-PAD prognosticate major vascular events and whether patients at high risk have a greater absolute benefit from low-dose rivaroxaban and aspirin.
Objective: To quantify the risk of major vascular events and investigate the response …
Authors
Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI
Journal
JAMA Cardiology, Vol. 6, No. 1, pp. 21–29
Publisher
American Medical Association (AMA)
Publication Date
January 1, 2021
DOI
10.1001/jamacardio.2020.4390
ISSN
2380-6583
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AgedAmputation, SurgicalAspirinCardiovascular DiseasesComorbidityDiabetes MellitusDouble-Blind MethodFactor Xa InhibitorsFemaleHeart FailureHemorrhageHumansMaleMiddle AgedMyocardial InfarctionPeripheral Arterial DiseasePlatelet Aggregation InhibitorsPrognosisRenal InsufficiencyRivaroxabanSeverity of Illness IndexStroke